英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
244890查看　244890　在百度字典中的解释百度英翻中〔查看〕
244890查看　244890　在Google字典中的解释Google英翻中〔查看〕
244890查看　244890　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nonstatin Cholesterol Medications - NEXLIZET® NEXLETOL®
    NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like stent placement or bypass surgery, in adults who were unable to take recommended statin treatment
  • NEXLIZET® NEXLETOL® HCP Information - Official Site
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • Nexlizet: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Nexlizet (bempedoic acid and ezetimibe) may be used to reduce LDL-C levels in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), alone or in combination with other LDL-C lowering therapies It should be used i
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Nexlizet (Bempedoic acid and Ezetimibe) for Heart Disease
    Overview Nexlizet is a prescription drug approved by the U S Food and Drug Administration (FDA) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • Nexlizet Patient Tips: 7 things you should know - Drugs. com
    The bempedoic acid component of Nexlizet also reduces the risk of a heart attack or revascularization procedures in statin-intolerant patients with or at risk for cardiovascular disease
  • Esperion’s Nexletol and Nexlizet Receive FDA Approval for . . .
    The United States approvals of Nexlizet and Nexletol for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial assessing the effect of Nexletol on cardiovascular outcomes in approximately 14,000 patients with or at high risk of cardiovascular disease (CVD)
  • What Is NEXLIZET® - Learn How It Works Get Answers
    The most common side effects of NEXLIZET in people with heart problems include: Kidney problems, anemia, increased liver enzymes, muscle spasms, and gallstones NEXLIZET can cause serious side effects, including: Increased levels of uric acid in the blood, which can lead to gout, a painful joint condition





中文字典-英文字典  2005-2009